The Wnt signaling pathway is involved in normal embryonic development and controls the homeostatic self-renewal of stem cells in adult tissues. Constitutive activation of Wnt signaling contributes to cancer development and progression. We identified a CXXC4 homozygous deletion at 4q24 in an aggressive renal cell carcinoma (RCC) using single-nucleotide polymorphism (SNP) arrays. CXXC4 encodes Idax, which negatively regulates Wnt signaling by binding to the PDZ domain of Dishevelled. CXXC4 mRNA levels in tumor samples were significantly lower in patients with metastases compared with those without (P ¼ 0.0016). Patients whose tumors had lower CXXC4 expression than normal kidney showed a poorer cause-specific survival outcome than those with higher expression (P ¼ 0.0095). Decreased expression of CXXC4 also correlated with cytoplasmic staining of b-catenin. Knockdown of CXXC4 induced the nuclear translocation of b-catenin and altered expression of a set of genes involved in cell proliferation, invasion and survival. Furthermore, reduced expression of CXXC4 by small interfering RNAs promoted cell proliferation and inhibited apoptosis after 5-FU and doxorubicin treatment in RCC cells. These data suggest that CXXC4 plays a critical role in tumor progression of RCC through Wnt signaling. Wnt signaling could thus be a potential molecular target in RCC indicating decreased CXXC4 expression.
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Introduction
Renal cell carcinoma (RCC) is increasing in incidence, and 30% of RCC patients present with metastatic disease at initial diagnosis. Approximately 30% of the patients undergoing nephrectomy for clinically localized RCC advance to metastatic disease (Levy et al., 1998) . Surgical resection is curative for most localized RCCs, but in cases of metastatic or recurrent disease conventional therapies including chemotherapy, radiotherapy and immunotherapy have generally had only limited success in a small proportion of patients. Recently, sorafenib and sunitinib, two orally delivered multitargeted receptor tyrosine kinase inhibitors, were approved as a new treatment for advanced RCC (Escudier et al., 2007; Motzer et al., 2007) . Studies of such agents encourage the use of new targeted therapies to improve outcomes for patients with RCC.
Loss of function of the von Hippel-Lindau gene is most likely to be the initiating step in renal carcinogenesis and causes the accumulation of hypoxia-inducible factor and the deregulated activation of its target genes-VEGF, PDGF, TGFA, SLC2A1 and other hypoxia-inducible genes (Cohen and McGovern, 2005) . It is presumed that further genetic and/or epigenetic alterations are needed for progression of the disease, but the molecular basis for this in RCC remains unknown.
Comparative genomic hybridization has been used to examine chromosomal copy number changes in many types of cancer, including RCC. Although many genetic alterations have been identified by this method, putative tumor suppressor genes and oncogenes located in the affected loci in RCC have not yet been clarified due to the currently limited resolution of comparative genomic hybridization methods. Recently, single-nucleotide polymorphism (SNP) arrays (Matsuzaki et al., 2004) have made it possible to detect copy number alterations at higher resolutions (Bignell et al., 2004) .
In this study, we applied SNP array to RCC for detecting high-resolution copy number alterations and identified a homozygous deletion of the CXXC4 gene, a negative regulator of Wnt signaling, in an advanced RCC tumor. Further analysis of CXXC4 mRNA levels in RCC and additional knockdown experiments revealed that the impairment of CXXC4 expression activates Wnt/b-catenin signaling and promotes cell proliferation and survival in RCC cells.
Results
Homozygous deletions on 4q, 9p and 10q in an aggressive case of RCC We performed copy number analysis of 23 RCC cases using a 50K SNP array. Copy number analyses of an advanced case of this tumor showed a unique pattern of multiple homozygous deletions within a region of less than 1 Mb at 4q24, 9p21.3 and 10q25.2. The genes and their physical positions on the affected chromosomal loci are shown in Table 1 . The deleted region at 4q24 contains the LOC391679 and TAXREB107 genes. The CXXC4 and KIAA1546 genes are located between the SNPs, calculated as zero and one copy.
We focused on CXXC4 for further analyses as it encodes Idax, which is a negative regulator of Dishevelled (Dvl) in the Wnt signaling pathway (Hino et al., 2001; Michiue et al., 2004) . To confirm the relative DNA quantity between the cancerous region and corresponding normal tissue in this case, we performed quantitative realtime-PCR (qRT-PCR) using primer sets for the regions indicating two (D4S1587), one (STS64905 and STS55593) and zero copies (CXXC4 and STS70240) in the SNP array analysis (Figure 1a) . The relative quantification values were calculated as 0.98 ± 0.01, 0.61 ± 0.02, 0.60 ± 0.01, 0.24 ± 0.01 and 0.29 ± 0.01 by qRT-PCR for D4S1587, STS64905, STS55593, STS70240 and CXXC4 regions, respectively ( Figure 1b) . These results indicate that the CXXC4 gene is a target gene for homozygous deletion at 4q24 in aggressive RCC.
Decreased expression of CXXC4 correlates with metastasis, high tumor grade and a poor survival outcome in RCC We further examined the CXXC4 mRNA levels by qRT-PCR using a sample cohort of 92 RCCs (Figure 2a ). Tumor CXXC4 mRNA levels were significantly lower in patients with metastases (0.73±0.90) compared with those without (1.76 ± 1.32) (P ¼ 0.0016). They were also significantly lower in patients with stage IV RCCs (0.70±0.88) compared with stage I cases (2.00 ± 1.33) (P ¼ 0.0007), and were also lower in patients with Grade III (0.91 ± 1.06) compared with Grade I (2.40±1.56) and Grade II lesions (1.75±1.27) (P ¼ 0.0071 and 0.01, respectively). In terms of histology, CXXC4 expression was significantly lower in the spindle cell-type RCC, the most malignant version of this cancer, (0.17±0.17) compared with the clear cell type (1.68 ± 1.31; P ¼ 0.032) (Supplementary Figure S1) . Moreover, patients with lower levels of CXXC4 mRNA in their tumor samples (n ¼ 43) had a poorer cause-specific survival outcome compared with the higher expression cases (n ¼ 49; 5-year cancer-specific survival, 51 and 86%, respectively; P ¼ 0.0095) (Figure 2b ). It is also noteworthy that none of the patients with high CXXC4 expression (n ¼ 43) showed tumor recurrence, whereas five of those with lower CXXC4 expression (n ¼ 28) had disease recurrence after nephrectomy. The 5-year recurrencespecific survival rates were 100 and 63% in high and low CXXC4 expression patients, respectively (P ¼ 0.0021) (Figure 2c ).
Cytoplasmic b-catenin expression correlates with decreased CXXC4 expression in RCC Because CXXC4 is a negative regulator in the Wnt/ b-catenin signaling pathway, we investigated whether CXXC4 expression affects b-catenin expression in RCC. We tested the expression of b-catenin in 92 paraffin-embedded tissues that have been analysed by qRT-PCR for CXXC4 mRNA by immunohistochemistry ( Figure 3A ). Among the 92 RCCs examined, nine samples were excluded because of an undetectable expression of b-catenin in the corresponding normal tissue. Using the remaining 83 samples, we analysed the relationship between cytoplasmic b-catenin levels and CXXC4 mRNA levels. Twenty-two (26.5%) of these 83 RCCs showed abundant cytoplasmic b-catenin, and the corresponding CXXC4 mRNA levels were significantly lower in tumors showing cytoplasmic b-catenin expression (0.61±0.81) compared with tumors without cytoplasmic b-catenin (1.90 ± 1.30; Po0.0001) ( Figure 3B ). In addition, cytoplasmic b-catenin expression was significantly related to high tumor grade and stage (Table 2 ). These data suggest that reduced CXXC4 expression and concomitant activation of Wnt signaling are involved in the development of an aggressive form of RCC.
The knockdown of CXXC4 induces b-catenin nuclear translocation and gene expression downstream of Wnt/ b-catenin signaling To examine the effects of decreased CXXC4 expression on the genes that are downstream of Wnt signaling, we Number of SNPs that are calculated as homozygous deletion continuously at homozygous deletion.
b Genes located at the region between SNPs calculated as zero and one copy.
CXXC4 and progression of RCC T Kojima et al performed knockdown studies of CXXC4 and measured mRNA levels of representative Wnt-signaling targets. The expression levels of these genes were analysed by qRT-PCR after transfection of two non-overlapping CXXC4 siRNAs (small interfering RNA) (si no. 1 and si no. 2) in SKRC-59 cells. Because CXXC4 antibody was not available, we confirmed the downregulation of CXXC4 in mRNA levels by qRT-PCR. We performed qRT-PCR in triplicates at least three times to confirm the reduced expression of CXXC4. These CXXC4 siRNAs were highly effective, and reduced CXXC4 expression to 12 and 16% of the levels in control siRNA SKRC-59 cells, respectively. As shown in Figure 4a , representative Wnt downstream genes, including CCND1, EPHB2, SPARC and MMP7, were significantly upregulated and CDKN1A was downregulated by CXXC4 siRNAs. The knockdown of CXXC4 increased the fraction of cells showing nuclear localization of b-catenin, while its cytoplasmic accumulation was not evident (Figure 4b ).
Knockdown of CXXC4 promotes cell proliferation and resistance to apoptotic therapeutic agents in RCC cell lines To study the potential role of CXXC4 in tumor progression and the development of an aggressive RCC phenotype, we examined the effects of CXXC4 knockdown on cell proliferation and apoptosis using two non-overlapping CXXC4 siRNAs (si no. 1 and si no. 2) in SKRC-59 cells. CXXC4 knockdown significantly promoted cell proliferation at 96 h (si no. 1) and 48 and 72 h (si no. 2) (Figure 4c ). Caspase activity induced by doxorubicin and 5-FU (5-fluorouracil) were also significantly decreased in cells transfected with CXXC4 siRNAs compared with control siRNA cells (Figure 4d ). To further understand the molecular mechanisms of RCC progression and the aggressive phenotype induced by decreased CXXC4 expression, we analysed gene expression profiles in SKRC-59 cells after CXXC4 knockdown (si no. 1) using GeneChip arrays.
Reduction of CXXC4 modulates the expression of genes involved in cell proliferation, invasion and survival The genes regulated by CXXC4 knockdown are listed in Supplementary Table 1 . This group includes genes related to cellular proliferation-FGF18, EGR1 and MYCN were upregulated, DUSP6 was downregulated and tumor invasion-SDF1, EDN2, L1CAM and PLAUR were upregulated. CXXC4 knockdown also affected genes that modulate apoptosis-BIRC7 CXXC4 and progression of RCC T Kojima et al (baculoviral inhibitor of apoptosis protein repeat-containing protein 7) (livin), CA9 and SOD2 were upregulated, XAF1 (XIAP-associated factor-1) and APAF1 were downregulated. These results indicate that reduced CXXC4 expression influences genes that control cell proliferation, invasion and survival.
Discussion
The CXXC4 gene maps to 4q24 and encodes the Idax protein, which binds to the PDZ domain of Dvl and inhibits the Dvl and Axin complex. Idax also suppresses the Wnt-induced accumulation of b-catenin and activation of T-cell factor (Hino et al., 2001; Michiue et al., 2004) . To our knowledge, we have provided the first evidence of a functional role of CXXC4 in cancer. The Wnt/b-catenin signaling pathway plays an important role in tumorigenesis and progression in various cancers (Barker and Clevers, 2006) . The role of Wnt/b-catenin signaling in RCC, however, is not yet fully understood. APC gene mutations are not involved in RCC (Suzuki et al., 1997) , and b-catenin mutations are rare events in these tumors (Bilim et al., 2000) . Recently, the decreased expression of negative regulators of Wnt signaling, SFRP1 and DKK-3, has been found in RCC (Kurose et al., 2004; Dahl et al., 2007; Gumz et al., 2007) . However, it is noteworthy that these results were obtained irrespective of the tumor grade or stage. In this study, we found that the CXXC4 mRNA levels were gradually decreased in RCC as the tumor stage and grade increased. Notably also, the cytoplasmic b-catenin levels correlated with decreased CXXC4 expression. The cytoplasmic accumulation of b-catenin was observed in some but not in all RCC tumor samples, and was predominantly found in aggressive cases. In the cell line experiment, cytoplasmic accumulation of b-catenin following the knockdown of CXXC4 was not evident but it was concentrated in the nucleus (Figure 4b ). Cytoplasmic accumulation of b-catenin seen in the patients' samples may be interpreted as indicating a stage before its migration to the nucleus. Significant correlations between overexpression of cyclin D1 involved in the Wnt signaling pathway and accumulation of b-catenin in the cytoplasm have been reported by several investigators (Qiao et al., 2001; Ueta et al., 2002) . In contrast to CXXC4, we observed loss of SFRP1 expression in almost all RCCs, including cases showing membranous staining of b-catenin (data not shown). One possible functional role of Idax (CXXC4) in RCC is depicted in Figure 5 . In early stage RCC, Idax negatively regulates Wnt signaling, which may be activated by the downregulation of SFRP1 and DKK-3. In advanced stage RCC, the impaired regulation of Wnt signaling through decreased CXXC4 causes b-catenin accumulation and promotes disease progression through downstream gene activation. It is also possible that the planar cell polarity pathway, including RhoA and Rac, may be activated by decreased CXXC4, although we have not examined that pathway in this study.
In SKRC-59 cells, CXXC4 knockdown was found to induce b-catenin nuclear translocation, upregulate the expression of Wnt signaling downstream genes, promote cell proliferation and confer resistance to two cytotoxic agents. Microarray analyses further identified genes regulated by CXXC4-mediated signaling that are involved in cell proliferation, invasion and survival.
Examples include BIRC7, L1CAM, PLAUR and FGF18, which are all downstream targets of Wnt/bcatenin signaling (Mann et al., 1999; Shimokawa et al., 2003; Gavert et al., 2005; Yuan et al., 2007) . PLAUR and SERPINE1 are components of the urokinase plasminogen activator system, and the overexpression of these genes has been correlated with a high-grade tumor and poor survival outcomes in RCC (Swiercz et al., 1998; Ohba et al., 2005) . Livin is a member of the inhibitor of apoptosis protein family and can limit apoptosis by inhibiting the proteolytic activation of CXXC4 and progression of RCC T Kojima et al caspases 3, 7 and 9 (Kasof and Gomes, 2001 ). In RCC, Livin expression was significantly increased in the tumor tissues , and BIRC7 RNAi sensitized these RCC cells to proapoptotic stimuli . We also identified several novel genes in these experiments. XAF1 antagonizes anticaspase activity of baculoviral inhibitor of apoptosis protein repeat-containing protein 4 (BIRC4) and is considered to be putative tumor suppressor gene (Liston et al., 2001) . XAF1 is ubiquitously expressed in normal tissues, but is present at low or undetectable levels in many cancers including RCC (Lee et al., 2006) . Low XAF1 mRNA expression levels have been correlated with an unfavorable clinical course in RCC patients (Kempkensteffen et al., 2007) . Thus, CXXC4 might be a key modulator of signaling, and its downstream genes may be involved in the development of a malignant phenotype in RCC.
The mechanisms underlying the downregulation of CXXC4 remain unclear. Loss of 4q was observed in 10-50% of RCCs examined previously by conventional and array comparative genomic hybridization (Moch et al., 1996; Jiang et al., 2000; Yoshimoto et al., 2007) . Several additional studies of RCC have also indicated that the loss of 4q is associated with sarcomatoid transformation and high-grade tumors (Jiang et al., 1998; Yoshimoto et al., 2007) . In Wilms' tumors, a 2.4-Mb minimal region of loss of heterozygosity has been detected at 4q24-q25 by 10K SNP array, which is a CXXC4 and progression of RCC T Kojima et al region that includes the CXXC4 gene (Yuan et al., 2005) . Interestingly, loss of 4q has been detected in 46-77% of colon, cervix and hepatocellular carcinomas (Mitra et al., 1994; Ried et al., 1996; Yeh et al., 1996) suggesting that aberrant Wnt signaling may be implicated in the formation of several cancer types. Other mechanisms, such as mutations or aberrant methylation, may suppress the expression of CXXC4 during the progression of RCC. Recently, CXXC4 was revealed to be one of several genes downregulated by ZNF217 binding (Krig et al., 2007) . Thus, transcriptional regulation could be a mechanism to suppress the expression of CXXC4.
In conclusion, our present data provide evidence that Wnt signaling is activated by decreased CXXC4 expression and correlates with a more aggressive phenotype in RCC. CXXC4 levels in tumors could thus serve as a diagnostic marker of tumor recurrence. In addition, regulator proteins in the Wnt signaling pathway are possible molecular targets for future therapies against metastatic RCC.
Materials and methods
Cell culture and reagents SKRC-59 cells (a gift from Dr JG Old, Memorial Sloan Kettering Cancer Center, NY, USA) were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum and 1% L-glutamine at 37 1C and a 5% humidified CO 2 atmosphere. 5-FU and doxorubicin were purchased from Sigma (St Louis, MO, USA) and Biomol (Plymouth Meeting, PA, USA), respectively.
Patients
All of the primary RCC tumors and corresponding normal samples analysed in this study were collected after surgical procedures. Ethical approval and prior patient consent were obtained in each case. The surgical specimens were snap-frozen in liquid nitrogen and stored at À80 1C until use. The corresponding patient characteristics are summarized in Supplementary Table S2 . Tumor stages and pathological grades were assigned according to the general rules developed by the Japanese Urology Association, the Japanese Society of Pathology and the Japan Radiological Society (3rd Edition). This rule is according to the criteria of histological cell types and TNM staging of the Union International Contre le Cancer and the American Joint Committee on Cancer (Guinan et al., 1997; Storkel et al., 1997) . Pathological grades were assigned according to a system developed by the Japanese Urological Association, based on the degree of atypia of tumor cells. The tumors were classified as grade 1 atypia, when the nucleus was smaller in size than normal epithelial cells, grade 2 atypia, when the nucleus was equal in size to normal epithelial cells and grade 3 atypia, when the nucleus was larger in size to normal epithelial cells and was polymorphic.
50K GeneChip assay
GeneChip 50K SNP mapping array analysis was performed according to the standard Single Primer GeneChip Mapping Assay protocol using a Human Mapping 50K Array HindIII (Affymetrix, Santa Clara, CA, USA). Individual SNP copy numbers and chromosomal regions with gains or losses were evaluated using CNAG version 2.0 software (Nannya et al., 2005) . A decrease in the Idax (CXXC4) levels promotes TCF activity and contributes to RCC progression. The decreased expression of SFRP1 and DKK-3, both Wnt signaling negative regulators have been observed in both early and advanced RCC (Kurose et al., 2004; Dahl et al., 2007; Gumz et al., 2007) .
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DNA quantitative PCR
A SYBR Green Master Mix was used for PCR, and the reactions were analysed in triplicate with an ABI PRISM 7900HT (Applied Biosystems, Foster City, CA, USA) using the DDCT method. The PCR conditions were as follows: denaturing at 95 1C for 10 min, followed by 40 cycles of 95 1C for 15 s and 58.5 1C for 1 min. As an internal control, Line-1 was used (Wang et al., 2002) . The primers used for examination of 4q deletions are listed in Supplementary Table  S3 .
qRT-PCR Quantitative RT-PCR was performed using the TaqMan Gene Expression assay and an ABI PRISM 7900HT (Applied Biosystems). The PCR conditions were as follows: initial incubation at 50 1C for 2 min and denaturing at 95 1C for 10 min, followed by 40 cycles of 95 1C for 15 s and 60 1C for 1 min. RNA expression levels were compared using an RNA pool from 40 samples of a normal kidney region. 18s RNA was used as an internal control.
Immunohistochemistry and immunocytochemistry
Formalin-fixed paraffin-embedded sections were microwaved for antigen retrieval and incubated with an anti-b-catenin monoclonal antibody (1:100; Transduction Laboratories, San Jose, CA, USA). Immunostaining was then performed using a standard immunoperoxidase technique (Histofine SAB-PO Kit, Nichirei Co., Tokyo, Japan). The color reaction was developed with 3,3 0 -diaminobenzidine tetrahydrochloride/ 0.03% H 2 O 2 , counterstained with hematoxylin and mounted. Immunostaining signals that were found exclusively at cell-cell borders were considered to be membranous staining. If a signal accumulation was observed in the cytoplasm in more than 20% of the tumor cells, this was regarded as cytoplasmic accumulation.
Cells were fixed in 4% paraformaldehyde and permeabilized in 0.2% Triton X-100 solution, followed by blocking in 1% bovine serum albumin solution. Staining was carried out using anti-b-catenin antibodies with an FITC conjugate (1:400; Transduction Laboratories).
Knockdown of CXXC4 by siRNA and assay of proliferation and apoptosis Transfections were carried out using Lipofectamine RNAi-MAX (Invitrogen, Paisley, UK). siRNAs against CXXC4 (si no. 1, HSS149462; si no. 2, NM 025212.1_stealth_499) and corresponding negative controls (Stealth RNAi Negative Control Low GC Duplex) were purchased from Invitrogen. SKRC59 cells were seeded onto 96-well plates (5 Â 10 3 cells per well) and transfected with siRNAs specific for CXXC4 or negative control siRNA (1.7 nM). Cell proliferation was assessed using a WST-8 assay (Dojindo, Tokyo, Japan) according to the manufacturer's instructions. Each experiment was performed in triplicate. For apoptosis assays, SKRC59 cells were first cultured in white-walled 96-well plates and transfected with siRNAs specific for CXXC4 or negative control. 5-FU and doxorubicin were added at 24 h after transfection. After an additional 48 h incubation, the activity of caspases 3 and 7 was measured using the Caspase-Glo3/ 7-assay (Promega, Madison, WI, USA).
Expression profiling
Samples of RNA were isolated from SKRC-59 cells at 48 h after siRNA transfection using an RNeasy Kit (Qiagen, Valencia, CA, USA). The synthesis of biotin-labeled cRNA probes, and the hybridization, washing, staining and scanning steps were performed according to the manufacturer's instructions (Affymetrix). Microarray experiments were carried out using Human Genome U133 Plus 2.0 arrays. Data was analysed with GeneSpring GX 7.3.1 (Silicon Genetics, Redwood City, CA, USA).
Statistical analysis
Data are expressed as the mean ± s.d. The Fisher's exact probability test was applied to assess the relationship between cytoplasmic b-catenin expression and clinical parameters. Analysis of variance followed by the Tukey or Dunnett posttest were used to compare the expression levels of CXXC4 with tumor stage and grade or pathological type, respectively. Clear cell RCC samples were used as the control for the Dunnett post-test. The significance of the in vitro data was determined by the Student's t-test. Cause-specific and recurrence-free survival was estimated using the Kaplan-Meier method, and the differences were compared by the log-rank test. All tests were considered to be statistically significant at Po0.05.
